New Ophthalmology Products to be Introduced to Market Soon, Says GBI Research in Its Study Available at MarketPublishers.com
21 Nov 2016 • by Natalie Aster
LONDON – The human visual system can be impacted by a number of pathological conditions leading to different vision problems like the eye dry syndrome, glaucoma, diabetic macular edema, and more.
The dry eye symptoms can be generally controlled, but other diseases are not so easy to cope with. They are chronic, progressive and incurable. They can lead to visual impartment. Blindness is one more probable final.
There is a wide range of novel molecular targets that has been revealed over the last years. At present, more than 780 pipeline products are in the ophthalmology therapy area pipeline.
Approximately 160 first-in-class pipeline products in the development for ophthalmology indications, making up around 40% of approximately 440 pipeline products for which exists a disclosed molecular target.
A large number of first-in-class products in the current pipelines have been engaged co-development and licensing deals.
Insightful research report “Frontier Pharma: Ophthalmology Therapeutics” worked out by GBI Research offers a comprehensive guide to the global ophthalmology therapeutics landscape. The study sheds light on the clinical and commercial landscape.
It assesses innovations in the clinical products landscape. The report covers product developments and looks at the molecular target landscape. The research study focuses on first-in-class therapies and molecular targets. It explores deals and strategic consolidations, as well.
Reasons to Buy:
- keep abreast of the latest trends and developments of the ophthalmological landscape;
- understand a structure this market has;
- learn which product and companies lead the race;
- see which potential first-in-class targets have;
- find out which commercial opportunities this market has.
Other Markets Analyzed by GBI Research Comprise:
- Cardiovascular Diseases
- Gastrointestinal Drugs
- Rheumatoid Arthritis
- Chronic, Acute and Neuropathic Pain
- Diabetes and Obesity Drugs
Other publications by our market research partner are available at its page.